Clinical Trials Browser

INDUSTRY × tisagenlecleucel × 1 year × Clear all

Burkitt Lymphoma, Neoplasm, Residual

NCT06785818 2026-02-23

Long-term Follow up Local Registry Study of Kymriah in South Korea

Recruiting

500 enrolled

Lymphoid

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT05888493 2026-02-20

LEDA

Phase 3 Active not recruiting

109 enrolled

Lymphoid

Lymphoma, Follicular, Recurrence

NCT04094311 2026-02-17

Study of Out of Specification for Tisagenlecleucel

Phase 3 Recruiting

200 enrolled

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03601442 2025-12-05

CTL019 Out of Specification MAP for ALL or DLBCL Patients

Available

LymphoidOther hematologic neoplasm

Recurrence, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05075603 2025-10-23

Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

Phase 1 Completed

17 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03568461 2025-10-07

ELARA

Phase 2 Completed

98 enrolled 9 charts 1 FDA

Lymphoid

Lymphoma, Follicular, Recurrence

NCT05541341 2025-06-06

Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies

Recruiting

200 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

CASSIOPEIA

Long-term Follow up Local Registry Study of Kymriah in South Korea

LEDA

Study of Out of Specification for Tisagenlecleucel

CTL019 Out of Specification MAP for ALL or DLBCL Patients

Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

ELARA

Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies